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Abstract
Background: The implantable cardioverter defibrillator (ICD) is generally well accepted, but 25-33% of
patients experience clinical levels of anxiety, depression, and impaired quality of life (QoL) following
implantation. Few trials in ICD patients have investigated whether behavioral intervention may mitigate
the development of these adjustment problems. We present the rationale and study design of the WEB-
based distress management program for implantable CARdioverter dEfibrillator patients (WEBCARE)
trial.
Methods: WEBCARE is a multi-center, multi-disciplinary, randomized, controlled behavioral intervention
trial designed to examine the effectiveness of a web-based approach in terms of reducing levels of anxiety
and device concerns and enhancing QoL. Consecutive patients hospitalized for the implantation of an ICD
will be approached for study participation while in hospital and randomized to the intervention arm (n =
175) versus usual care (n = 175) at baseline (5-10 days post implantation). Patients will complete
assessments of patient-centered outcomes at baseline, 14, 26, and 52 weeks after implantation. Patients
randomized to the intervention arm will receive a 12-week web-based behavioral intervention starting 2
weeks after implantation. Primary endpoints include (ii) patient-centered outcomes (i.e., anxiety,
depression, ICD acceptance, QoL); (iii) health care utilization; and (iiii) cost-effectiveness. All primary
endpoints will be assessed with standardized and validated disease-specific or generic questionnaires.
Secondary endpoints include (iii) cortisol awakening response; and (iiii) ventricular arrhythmias.
Discussion: WEBCARE will show whether a behavioral intervention using a web-based approach is
feasible and effective in reducing anxiety and ICD concerns and improving QoL in ICD patients.
Trial Registration: http://www.ClinicalTrials.gov. Identifier: NCT00895700.
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Background
Implantable cardioverter defibrillator (ICD) therapy is
considered the treatment of choice for the prevention of
sudden cardiac death (SCD) both in patients who have
survived life-threatening arrhythmias (secondary preven-
tion) and in patients at risk for these arrhythmias due to
coronary artery disease and left ventricular dysfunction
(primary prevention) [1]. The number of ICD implanta-
tions has risen considerably, since the first ICD was
implanted in humans [2-4]. This increase in implantation
rates can in part be attributed to expansion of the indica-
tions for ICD implantation to also include primary pre-
vention, due to ICD therapy being superior to anti-
arrhythmic drugs in the prevention of SCD in these high-
risk patients [5-7].
Despite the medical benefits of ICD therapy, and the
device generally being well accepted by the majority of
patients [8], 25-33% of patients experience clinical levels
of anxiety, depression, and impaired quality of life (QoL)
following implantation [9-12]. These difficulties may be
attributed to actual ICD shocks [13,14], but also to device-
related concerns including fear of shocks [15,16], ICD
advisories (i.e., a notification from ICD manufacturers
that the hardware may potentially malfunction) [17], and
the psychological make-up of the patient, including lack
of optimism [18] and personality factors, such as the dis-
tressed (Type D) personality [11,12,19]. The prevention of
the manifestation of psychological distress in ICD
patients is important, given preliminary evidence that dis-
tress may increase the risk of ventricular tachyarrhythmias
[20-22]. Hypercortisolemia, reflecting a dysregulation of
the hypothalamus-pituitary-adrenocortical axis, may pro-
vide one of the mechanisms linking psychological factors
to ventricular tachyarrythmias due to increased inflamma-
tion arising from chronic stress [23].
Preliminary evidence suggests that ICD patients benefit
from psychological and behavioral intervention, with the
largest effect being found in reductions of symptoms of
anxiety and improved exercise capacity [24]. One inter-
vention trial has also found a reduction in cortisol levels
[25]. However, the number of large-scale intervention tri-
als in ICD patients is scarce [24,26], with the majority of
these trials having used a nurse-based approach, cognitive
behavioral therapy as stand-alone therapy, or in combina-
tion with cardiac rehabilitation. A web-based intervention
may be equally effective and have advantages over these
more traditional forms [27]. Advantages of a web-based
intervention include its low-threshold accessibility via the
internet, which makes it logistically feasible for most
patients to participate, as they do not have to take time off
work, but can access the intervention at home in their
own time. In addition, a web-based approach safeguards
the patient's anonymity, and the patient avoids the stigma
associated with traditional, face-to-face therapy. Such an
approach may be particularly useful for patients with a
Type D personality profile, who are at increased risk of
adverse health outcomes, as they do not share their emo-
tions in social interactions due to fear of rejection [28].
Design
The  WEB-based distress management program for
implantable  CARdioverter dEfibrillator patients (WEB-
CARE) is a Dutch multi-center, multi-disciplinary, rand-
omized, controlled behavioral intervention trial designed
to examine the effectiveness and feasibility of a web-based
approach in terms of reducing levels of anxiety and device
concerns and enhancing QoL in ICD patients. The trial
has been registered on http://www.ClinicalTrials.gov
(NCT00895700).
Study population and eligibility criteria
Consecutive patients (N = 350) hospitalized for the
implantation of an ICD in three medical centers in The
Netherlands will be approached for study participation
while in hospital and randomized to the intervention arm
(n = 175) versus usual care (n = 175) at baseline (5-10
days post implantation). Patients (i) being implanted
with an ICD, (ii) between 18-75 years of age, (iii) speak-
ing and understanding Dutch, (iv) with access to and abil-
ity to use the internet, and (v) providing written informed
consent will be eligible to participate. Patients with a life
expectancy less than 1 year, with a history of psychiatric
illness other than affective/anxiety disorders, on the wait-
ing list for heart transplantation, or with insufficient
knowledge of the Dutch language will be excluded.
Study procedure, randomization and follow-up
The study protocol will be approved by the medical ethics
committees of the participating centers. The study will be
conducted according to the Declaration of Helsinki, as
amended in 2008 by the World Medical Association, and
all patients will be informed orally and in writing about
the purpose, rights, and possible benefits/risks of the
study.
Patients will be invited to participate in the study while
hospitalized for their ICD implantation. Patients
responding positively to the invitation will be given the
informed consent form and the baseline questionnaire
package. In order to avoid measuring pre-operative stress,
patients will be asked to complete the baseline assessment
between 5 and 10 days (T0) after implantation. If the base-
line questionnaire is not returned within 7 days, patients
will receive a reminder telephone call. When the signed
informed consent form and completed baseline assess-
ments are received at the trial coordinating center, the
coordinating center will randomize the patient either to
the treatment arm or to usual care. There will be a separateTrials 2009, 10:120 http://www.trialsjournal.com/content/10/1/120
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randomization list for each participating hospital. The
patient will be informed by telephone to which condition
he/she has been randomized and the procedure for the
rest of the study. If the patient is randomized to the inter-
net intervention, he/she will receive a login and password
in order to be able to access the intervention. The day of
randomization will be the first day of the intervention
period, with the duration of the intervention being 12
weeks. For both study conditions, the follow-up assess-
ments will take place 14 (T1), 26 (T2), and 52 weeks (T3)
post implantation. All randomized patients, irrespective
of condition, will be followed until the scheduled study
end. A schematic representation of the study design is
shown in Figure 1.
Study endpoints
Primary endpoints include (ii) patient-centered outcomes
(i.e., anxiety, depression, ICD acceptance, QoL); (iii)
health care utilization; and (iiii) cost-effectiveness of the
intervention. Secondary endpoints include (iii) cortisol
awakening response; and (iiii) ventricular arrhythmias.
Assessment of primary endpoints
All primary endpoints in addition to psychological fac-
tors, such as Type D personality [29], will be assessed with
standardized and validated measures shown to have
acceptable psychometric properties (Table 1). Disease-
specific measures include the Florida Shock Anxiety Scale
[30], the Minnesota Living with Heart Failure question-
naire [31], the ICD Patient Concerns questionnaire [16],
and the Florida Patient Acceptance Survey [32,33].
Assessment of secondary endpoints
Salivary cortisol will be assessed, using the Salivette (man-
ufactured by Sarstedt, Etten-Leur, The Netherlands), at 3
out of the 4 time points, corresponding to the assessment
of patient-centered outcomes and psychological variables
(i.e., T0 = 5 to 10 days after ICD implantation; T1 = 14
weeks post-implantation; T3 = 52 weeks post-implanta-
tion). Due to test-retest reliability characteristics of corti-
sol [34,35], samples will be taken on two consecutive
weekdays at each time point. Four samples will be taken
at each time point and on the consecutive day, that is (a)
when waking up, (b) 1/2 hour later, (c) 11.00 a.m., and
(d) 3.00 p.m. Samples will be sent to the coordinating
trial center, where they will be stored at -20°Celsius until
assayed.
Information on ventricular arrhythmias will be gathered
from the electrograms stored by the ICD that will be
reviewed and classified by two experienced electrophysi-
ologists from the EP staff of the participating centers, who
are blind to whether patients are assigned to the treatment
or usual care arm. In case the two reviewers disagree about
the diagnosis, a third one will be consulted to reach a con-
sensus. For each episode, the date, type, and mean cycle
length of the tachyarrhythmia will be recorded, as well as
the type and outcome of delivered ICD therapy. The
Schematic representation of the study procedure Figure 1
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arrhythmia will be classified as (1) ventricular tachyar-
rhythmia or (2) atrial tachyarrhythmia without a coexist-
ent ventricular arrhythmia. Therapy triggered by
ventricular tachyarrhythmia will be considered as appro-
priate, while therapy delivered for atrial tachyarrhythmia
(including atrial fibrillation, atrial flutter, atrial tachycar-
dia, sinus tachycardia) or T wave oversensing and noise
will be defined as inappropriate
Intervention versus usual care
Patients randomized to the treatment arm will receive an
internet-based intervention starting 2 weeks after implan-
tation. They will receive a username and password to
access the intervention via the web. Every week an auto-
mated email will be sent to the participants to explain the
contents and exercises for the coming week. All the infor-
mation, as well as the exercise forms, will be downloada-
ble from the website in case participants prefer to read the
information on paper. Master's level psychology students,
trained and supervised by psychologists will provide feed-
back on the completed exercises. This feedback is not
meant to be therapeutic; it will be directed toward master-
ing the problem-solving strategies. The maximum
amount of time the psychology students should spend on
feedback will be 60 minutes per participant. The compo-
nents of the intervention are presented in Table 2. The
intervention has to be completed within 12 weeks, as we
learnt in an earlier trial that one session a week is too fast
a pace for most people. A typical session takes about 30
minutes and consists of an introduction, a discussion of
the previous lesson's homework, new theory and home-
work for the subsequent week. The sessions are designed
to be followed on a weekly or two-weekly basis. These
time indications may vary among users. Besides the ses-
sions, the participants have several resources at their dis-
posal: a homework station, extra information, reading
tips, useful links, and addresses for additional help.
Patients randomized to the usual care arm will receive care
as it is standardly offered to ICD patients in the three cent-
ers, comprised of an information booklet about ICD treat-
ment, standard clinical follow-up visits, and home
monitoring of the device (if applicable).
Statistical analysis and power calculation
The trial is designed to show whether a web-based behav-
ioral intervention is effective in improving patient-cen-
tered outcomes compared to usual care. The power
analysis was performed in relation to anxiety as the pri-
mary endpoint, since anxiety is a pertinent outcome meas-
ure in ICD patients due to the unique feature of the ICD
Table 1: Patient-centered outcomes and psychological factors assessed in the trial
Construct Questionnaire T0 T1 T2 T3
Anxiety STAI-S State Trait Anxiety Inventory (state only) xxxx
FSAS Florida Shock Anxiety Scale xxxx
PDS Posttraumatic Stress Scale xxx
DAI-4 Denollet Anxiety Inventory xxxx
Depressive symptoms HADS Hospital Anxiety and Depression Scale xxxx
PHQ-9 Patient Health Questionnaire xxxx
Quality of life SF-12 Short Form Health Survey 12 xxxx
MLWFQ Minnesota Living With Heart Failure Questionnaire xxxx
ICD concerns ICDC ICD Patient Concerns Questionnaire xxxx
ICD acceptance FPAS Florida Patient Acceptance Survey xxxx
Health care utilization and cost-effectiveness TiC-P Trimbos/iMTA questionnaire for Costs associated with 
Psychiatric Illness
xx
Type D personality DS14 Type D Scale xxxx
T0 = Baseline; T1 = 14 weeks; T2 = 26 weeks; T3 = 52 weeks.
Table 2: Components of the 12-week web-based intervention
Components Topics dealt with
▪ Psycho-education about the ICD ▪ Emotional reactions to ICD therapy
▪ Problem-solving skills ▪ Which aspects of ICD therapy may lead to distress
▪ Cognitive restructuring ▪ How to deal with shocks
▪ Disease-specific issues and fears
▪ Relaxation training ▪ How to prevent the avoidance of activities
▪ Personalized feedback by a therapist via the computer ▪ Interpretation of bodily symptoms
▪ How to cope with uncertainty
▪ Help-seeking behaviour
▪ How to cope with stressTrials 2009, 10:120 http://www.trialsjournal.com/content/10/1/120
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being able to provide a shock. With (i) an expected
between group effect size of .30., based on a recent meta-
analysis of web-based intervention for symptoms of anxi-
ety and depression [36] and taking into consideration that
our population consists partly of patients with subclinical
anxiety and depression levels; (ii) alpha = 0.05; (iii)
power = 0.80 (two-sided test), 350 patients are needed
(i.e., 175 in each condition). Although we had a response
rate of 82% in an earlier study [16,19], based on a more
conservative response rate of 50%, 700 patients need to be
approached.
The effectiveness of the intervention will be examined
using the intention-to-treat principle, with the inclusion
of all randomized participants in the statistical analysis
regardless of whether they completed the intervention or
the follow-up measurements. Missing data will be
imputed using regression imputation techniques. Univar-
iable and multivariable regression analyses (both linear
and Cox proportional hazard regression analysis) and
analysis of variance and analysis of covariance with
repeated measures will be used to investigate the effect of
the intervention on the endpoints. The type of regression
analysis will depend on the endpoint in question. Demo-
graphic, clinical and psychological variables will be
included in multivariable analyses in order to control for
their potential confounding effects. A p-value < 0.05 will
be used to indicate statistical significance. All data will be
analyzed using SPSS 17.0 for Windows (SPSS Inc., Chi-
cago, Illinois).
Discussion
The ICD is generally well accepted by patients [8], but 25-
33% of patients experience clinical levels of anxiety,
depression, and impaired QoL following implantation [9-
12].
Preliminary evidence suggests that psychological and
behavioral intervention may mitigate the development of
adjustment problems in ICD patients, but the number of
large-scale intervention trials in ICD patients is scarce [25-
27]. In addition, all of these trials have used a nurse-based
approach, cognitive behavioral therapy as stand-alone
therapy, or in combination with cardiac rehabilitation. A
web-based intervention may be equally effective and have
advantages over these more traditional forms [28]. The
WEB-based distress management program for implanta-
ble CARdioverter dEfibrillator patients (WEBCARE) is a
multi-center, multi-disciplinary, randomized, controlled
behavioral intervention trial designed to examine whether
a web-based approach leads to better patient-centered
outcomes, in terms of reduced levels of anxiety and device
concerns and improved QoL. The trial aims to include 350
patients from three Dutch centers.
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